Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-13
2007-03-13
Owens, Amelia A. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S125000
Reexamination Certificate
active
10279851
ABSTRACT:
A class of binding ligands for cocaine receptors and other receptors in the brain. Specifically, a novel family of compounds shows high binding specificity and activity, and, in a radiolabeled form, can be used to bind to these receptors, for biochemical assays and imaging techniques. Such imaging is useful for determining effective doses of new drug candidates in human populations. In addition, the high specificity, slow onset and long duration of the action of these compounds at the receptors makes them particularly well suited for therapeutic uses, for example as substitute medication for psychostimulant abuse. Some of these compounds may be useful in treating Parkinson's Disease or depression, by virtue of their inhibitory properties at monoamine transporters.
REFERENCES:
patent: 3133073 (1964-05-01), Archer
patent: 3813404 (1974-05-01), Clark
patent: 4111827 (1978-09-01), Thompson et al.
patent: 5116543 (1992-05-01), Lentsch
patent: 5122361 (1992-06-01), Kung
patent: 5128118 (1992-07-01), Carroll et al.
patent: 5141959 (1992-08-01), Carroll et al.
patent: 5298499 (1994-03-01), Carroll et al.
patent: 5374636 (1994-12-01), Moldt
patent: 5380848 (1995-01-01), Kuhar et al.
patent: 5413779 (1995-05-01), Kuhar et al.
patent: 5490955 (1996-02-01), Hagan et al.
patent: 5496953 (1996-03-01), Kuhar et al.
patent: 5554626 (1996-09-01), Moldt
patent: 5736123 (1998-04-01), Carroll
patent: 5831095 (1998-11-01), Gonzalez et al.
patent: 5935953 (1999-08-01), Kuhar et al.
patent: 6013242 (2000-01-01), Davies et al.
patent: 6123917 (2000-09-01), Carroll
patent: 6329520 (2001-12-01), Carroll et al.
patent: 6358492 (2002-03-01), Kuhar et al.
patent: 6416735 (2002-07-01), Carroll et al.
patent: 6531481 (2003-03-01), Carroll et al.
patent: 6531483 (2003-03-01), Kuhar et al.
patent: 6538010 (2003-03-01), Carroll
patent: 6552032 (2003-04-01), Carroll et al.
patent: 6559159 (2003-05-01), Carroll et al.
patent: 6593348 (2003-07-01), Carroll et al.
patent: 6706880 (2004-03-01), Carroll et al.
patent: 6900228 (2005-05-01), Carroll et al.
patent: 2003/0158415 (2003-08-01), Carroll et al.
patent: 2003/0176434 (2003-09-01), Carroll
patent: 2003/0203934 (2003-10-01), Kuhar et al.
patent: 2004/0146518 (2004-07-01), Carroll et al.
Maarten E. A. Reith et al., “Structural Requirements for Cocaine Congeners to Interact with Dopamine and Serotonin Uptake Sites in Mouse Brain and to Induce Stereotyped Behavior”, Biochemical Pharmacology, vol. 35 , No. 7, pp. 1123-1129, 1986.
Australian Office Action Dated Jan. 25, 2000, 2pp.
PCT Written Opinion Dated Jul. 24, 1998, 5pp.
Australian Patent Office Examiner's first report received in corresponding application on Feb. 4, 2003.
F.I. Carroll, et al., J. Med. Chem., 2004, 47, pp. 6401-6409, Monamine Transporter Binding, Locomotor Activity, and Drug Discrimination Properties of 3-(4-Substituted-phenyl)tropane-2-carboxylic Acid Methyl Ester Isomers.
Nida Res. Monogr. (MIDAD4, 03618595); 1990, vol. 96, “Drugs Abuse: Chem., Pharmacol., Immunol., AIDS”, pp. 112-121, XP002116828, Research Triangle Inst., Research Triangle Park, 27709, NC, USA.
F.I. Carroll, et al., “Synthesis and ligand binding of 3,β.-(3-subsituted phenyl)-and 3β-(3,4-disubstituted phenyl)tropane-2β-carboxylic acid methyl esters”, Med. Chem. Res. (McReeb, 10542523), 1991, vol. 1, No. 6, pp. 382-387, XP002116826, Research Triangle Inst., Research Triangle Park, 27709, NC, USA.
J. Med. Chem. (JMCMAR, 00222623), Mar. 20, 1992, vol. 35, No. 6, pp. 969-981, XP002116827, Research Triangle Inst., Research Triangle Park, 27709, NC, USA.
J. Med. Chem. (JMCMAR, 00222623), 1993, vol. 36, No. 20, pp. 2886-2890, XP002116829, Research Triangle Inst., Research Triangle Park, 27709, NC, USA.
P. Kotain, et al., J. Med. Chem., 1996, vol. 39, pp. 2753-2763, “Synthesis, Ligand Binding, and Quantitative Structure-Activity Relationship Study of 3β-(4′-Substituted phenyl)-2β-heterocyclic Tropanes: Evidence for an Electrostatic Interaction at the 2β-Position”.
F.I. Carroll, et al., J. Med. Chem., 2004, vol. 47, pp. 296-302, “Synthesis, Monoamine Transporter Binding Properties, and Behavioral Pharmacology of a Series of 3β-(Substituted phenyl)-2β-(3′substituted isoxazol-5-yl)tropanes”.
F.I. Carroll, et al., J. Med. Chem., 1995, vol. 38, pp. 379-388, “Cocaine and 3β-(4′-Substituted phenyl)tropane-2β-carboxylic Acid Ester and Amide Analogues. New High Affinity and Selective Compounds for the Dopamine Transporter”.
Abraham Philip
Boja John W.
Carroll Frank I.
Kuhar Michael J.
Lewin Anita H.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Owens Amelia A.
Research Triangle Institute
LandOfFree
Cocaine receptor binding ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cocaine receptor binding ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cocaine receptor binding ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3724729